Navigation Links
Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease

BETHESDA, Md., March 13, 2007--New evidence suggests that if you could choose your parents, you could reduce your risk of cardiovascular disease. Researchers from the long-standing Framingham Heart Study (FHS), a program of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, report that people whose parents live longer were more likely to avoid developing high blood pressure, high cholesterol, and other risk factors for cardiovascular disease in middle age than their peers whose parents died younger. They also found that the risk factor advantages persisted over time.

According to the researchers, this is the first study to examine cardiovascular risk factors in the offspring of longer-lived individuals using independent and validated measurements of risk. The findings are consistent with other studies that have linked lower cardiovascular risk with parental longevity based on self-reports of family history.

"Characteristics of Framingham Offspring Participants with Long-Lived Parents, appears in the March 12 issue of the Archives of Internal Medicine.

In the study, researchers examined 1,697 offspring age 30 and older (average age 40) whose parents participated in the original FHS and had reached age 85 or died before January 1, 2005. They compared cardiovascular risk factors among the offspring based on whether both parents, one parent, or neither parent lived to 85 years or older. The risk factors included age, sex, education, cigarette smoking, blood pressure, cholesterol, and body mass index (BMI). In addition, they compared the offsprings' Framingham Risk Scores, a summary score based on the combined contribution of traditional cardiovascular risk factors.

In general, the group in which both parents survived to age 85 had significantly fewer participants with high blood pressure or who were current smokers, compared to those in which both parents or one parent had died. In addition, the middle-aged children of long-lived parents had significantly lower levels of blood pressure and blood cholesterol, and they had lower Framingham Risk Scores than those in which one or both parents had died. Overall, parental longevity did not significantly affect BMI. After 12 years of follow up, the offspring of longer-lived parents were also less likely to progress to high blood pressure and to generate higher risk scores, the researchers report.

NHLBI's Framingham Heart Study has studied the health of many of the Massachusetts towns residents since 1948. The community-based research program has been the source of key research findings regarding the contributions of hypertension, high cholesterol, cigarette smoking, and other risk factors to the development of cardiovascular disease. Now assessing a third generation of participants, Framingham Heart Study investigators are expanding their research into other areas such as the role of genetic factors in cardiovascular disease as well as the use of novel biomarkers and new diagnostic tests to identify individuals at high risk.

Daniel Levy, M.D., Director of the Framingham Heart Study, and other FHS investigators are available to comment on the study's findings as well as how modifiable risk factors can lower cardiovascular disease risk.

To schedule interviews, contact the NHLBI Communications Office at 301-496-4236.

RESOURCES:

Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NH LBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at www.nhlbi.nih.gov.

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.


CONTACT:
NHLBI Communications Office
301-496-4236
'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 2016 As illustrated by the ... month, the numbers and momentum of cannabis in the ... the billions, more research and development push the sector ... of Legal Marijuana Markets Report  from from ArcView Market ... of the increase in sector is attributed to adult ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... AMSTERDAM , May 24, 2016 ... auf den Markt gebracht, die es Ärzten erlaubt, ... überall zu behandeln: MDLinking kombiniert Live Streaming mit ... sicheren Umfeld zu kommunizieren. Mediziner in Europa, Afrika, ... haben sich bereits für die Plattform registriert. ...
Breaking Medicine Technology:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, ... public. , Dr. Maisel, founder of Retina Group of New York , ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair restoration ... to both Snapchat users and those who do not use the app. Dr. Mohebi, the ... new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership ... solutions, today announced the organization has earned its ISO 13485 certification, indicating the ... compliant with all rules and policies associated with ISO quality standard 13485. ...
(Date:5/26/2016)... ... ... The Lung Institute has partnered with the Gulfcoast North Area ... at their clinic in downtown Tampa. The class is complimentary for the public. Register ... a free downloadable 4 Week Smoking Cessation Guide for those who are ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps ... from daily practices, arts & crafts, discussions, and games all geared towards enhancing ... Evans have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global ...
Breaking Medicine News(10 mins):